Publications
5598 Results
- Journal / Conference
- Clinical Trials 2025;0(0). doi:10.1177/17407745241304065
- Year
- 2025
- Research Committee(s)
- Leukemia
- Study Number(s)
- MYELOMATCH
Evaluating the impact of stratification on the power and cross-arm balance of randomized Phase 2 clinical trials
- Journal / Conference
- Journal of Medical Internet Research vol. 27 | e66821
- Year
- 2025
- Research Committee(s)
- Breast
- Study Number(s)
- S0307
Augmenting Insufficiently Accruing Oncology Clinical Trials Using Generative Models: Validation Study
- Journal / Conference
- JAMA Netw Open. Mar 3;8(3):e250778
- Year
- 2025
- Research Committee(s)
- Cancer Care Delivery
- PMID
- PMID40080017
- PMC
- PMC11907310
Health Care Contact Days for Older Adults Enrolled in Cancer Clinical Trials
- Journal / Conference
- JNCI Monograph Mar 1;2025(68):3-9
- Year
- 2025
- Research Committee(s)
- Cancer Care Delivery
- PMID
- PMID39989044
- PMC
- PMC11848029
When to Adjust for Multiplicity in Cancer Clinical Trials
- Journal / Conference
- Cancer Control
- Year
- 2025
- Research Committee(s)
- Cancer Care Delivery
- PMID
- PMID40384469
- Study Number(s)
- S1912CD
Addressing Challenges in Research Aimed at Reducing Financial Toxicity Among Cancer Patients and Caregivers: An Example From the CREDIT Study (SWOG S1912CD)
- Journal / Conference
- European Urology Feb;85(2):171-176
- Year
- 2024
- Research Committee(s)
- Genitourinary
- PMID
- PMID37085425
- PMC
- PMC10662935
- Study Number(s)
- S1216
Bone biomarkers and subsequent survival in men with hormone sensitive prostate cancer: results from the SWOG S1216 phase III trial of androgen deprivation therapy with or without orteronel
- Journal / Conference
- Journal of Clinical Oncology Jul 1;42(19):2295-2305
- Year
- 2024
- Research Committee(s)
- Gastrointestinal
- PMID
- PMID38547438
- Study Number(s)
- CTSU/C80702
Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials
- Journal / Conference
- Leukemia Jan;38(1):58-66
- Year
- 2024
- Research Committee(s)
- Leukemia
- PMID
- PMID37935977
- Study Number(s)
- S1203
A randomized phase III study of standard versus high-dose cytarabine with or without vorinostat for AML
- Journal / Conference
- Clinical Cancer Research Jan 17;30(2):444-449
- Year
- 2024
- Research Committee(s)
- Genitourinary
- PMID
- PMID37966367
- PMC
- PMC10824507
- Study Number(s)
- S1314
Association of Molecular Subtypes with Pathologic Response, PFS, and OS in a Phase II Study of COXEN with Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer
- Journal / Conference
- Clinical Cancer Research Jan 5;30(1):33-38
- Year
- 2024
- Research Committee(s)
- Early Therapeutics and Rare Cancers
- PMID
- PMID37882676
- PMC
- PMC10842092
- Study Number(s)
- S1609